April 24, 2023 10:03 AM EDT
R&D
Cell/Gene Tx
FDA+

On Ver­tex and CRISPR Ther­a­peu­tics’ heels, blue­bird sub­mits sick­le cell gene ther­a­py to FDA

Lei Lei Wu

News Reporter

Blue­bird bio said Mon­day morn­ing it has sub­mit­ted an ap­pli­ca­tion for its sick­le cell ther­a­py to the FDA for po­ten­tial ap­proval …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times